| | |
We are so FIRED UP, we can't wait to start trading this morning! 🔥 With markets continuing to make new all-time highs seemingly every day, it has been one of the better trading environments in a long time. | If you're pumped too (and don't want to trade ALONE), then join us today for LIVE trading in the Market Master's Room and don't forget to check out ALL our services on special here (ending today)! | | FOCUS LIST🔎 | WENA - Up over 60% in the pre-market after announcing plans to advance patented Klotho Gene Therapy for neurodegenerative disorder treatments | PEGY - Up over 60% in pre after formalizing agreement with Conduit Capital for services and pursuit of working capital investment | ZAPP - 2nd day play: Up over 50% on technical breakout and short squeeze | | *sponsored by Sica Media | Today's spotlight stock has been one of the biggest winners this year, but not likely on a lot of people's radar: MAIA Biotechnology (MAIA). | We have talked about this one several times this year already, and if you were listening to us MAIA has delivered phenomenal results – up over 190% since the start of the year (so far!). | | MAIA got a little "overheated" around a month ago when the stock doubled in price over a few weeks and spiked to nearly $6. | The thing with momentum stocks like this is that they tend to bounce back; the only question is when? | Well, yesterday might have given us a good clue about a possible reversal. | While the trading has arguably been boring the last month as MAIA has consolidated from this recent pullback, focus on yesterday's trading highlighted below… | | You'll see that MAIA had a big drop in the morning that broke the trendline once again. | But here's what caught our attention – buyers finally returned to buy up that dip and push it back above the trendline again to end the day. | That is one of the best reversal signals I can think of. | When a stock is up nearly 200% on the year, there are obviously a lot of traders who like it and are waiting for the right opportunity to get back in. | I think we could be seeing that moment right now with MAIA. | If you want to read more about what we're seeing for MAIA, read our full report here and make sure you keep MAIA at the very top of your watchlist. | *Sponsored content/paid advertisement. Spend time right now doing your own research on the stock, and of course, always approach your trading in a responsible manner. Trading is very risky, and nothing is ever guaranteed, so never trade with more than you can afford to lose. Please read the full disclaimer at the bottom of this email as well so you are aware of additional risks and considerations. |
|
| | HOTLIST🔥 | WENA - Up over 60% in the pre-market after announcing plans to advance patented Klotho Gene Therapy for neurodegenerative disorder treatments | Anew Medical, Inc. (WENA) is a biopharmaceutical company that develops therapies for neurological and age-related disorders, and specialty diagnostics. | In the pre-market this morning, the company announced plans to advance its recently patented Klotho gene therapy program for neurodegenerative disorders. | ANEW stated it has compelling initial data suggesting that maintaining elevated levels of Klotho in the body significantly contributes to longer, healthier lifespans. | Conversely, the data reveals that individuals with depleted or lower-than-normal levels of Klotho are more susceptible to neurodegenerative disorders such as ALS, Alzheimer's, and Parkinson's Disease. ANEW will also investigate other age-related disorders associated with depleted Klotho levels, such as memory loss, osteoporosis, sarcopenia (muscle wasting), diabetes mellitus, and certain cardiovascular conditions. | ANEW has development plans to advance its program in three distinct areas: | FDA Clinical Trials: The development of therapeutics to treat neurodegenerative diseases and age-related disorders involves using an adenovirus (AAV) vector to deliver the secreted Klotho gene DNA sequence to neurons in the central nervous system (CNS). This approach aims to correct deficiencies in the levels of s-KL. | Klotho Diagnostics: The development and commercialization of a diagnostic that will enable healthcare providers to accurately quantify levels of Klotho gene and protein isoforms in blood samples. This tool will also provide ANEW with the necessary diagnostic to screen patients for its clinical trials. | Age-Related Disorders: ANEW plans to develop exploratory approaches to promote longevity in healthy populations using gene or cell-based Klotho therapies, as well as other genes of interest that are directly related to longevity. | The stock traded up over 60% in the pre-market after the press release. | | The $2.08 area has acted as support in the pre-market and will be an important level to watch. | Above it, targets to the upside are $2.20, $2.40, $2.80, $3, and then the pre-market high at $3.44. Beyond that, $4.20 and $4.72 come into play. | Below $2.08, targets to the downside are $1.82, $1.50 and then a gap fill at $1.20. | | PEGY - Up over 60% in pre after formalizing agreement with Conduit Capital for services and pursuit of working capital investment | Pineapple Energy Inc. (PEGY) engages in the sale, design, and installation of photovoltaic solar energy systems and battery storage systems in the United States. Its brand portfolio includes SUNation, Hawaii Energy Connection, E-Gear, Sungevity, and Horizon Solar Power. | In the after-hours yesterday, the company announced it has engaged Conduit Capital to provide structural internal support, staffing, and assistance with capital raising activities. | Conduit Capital is a group known for connecting companies to mission aligned investors. The partnership also includes the addition of key talent to assist the Pineapple team, all of whom have industry-specific experience in Pineapple's various business sectors. | This includes Robert Zulkoski, Andy Childs, and Melissa Obegi, who each have a distinguished background of successful capital raises, M&A completions and corporate restructuring transactions. | The stock traded up over 60% in the pre-market in reaction to the news. | | The $2.03 area acted as support in the pre-market and now becomes a potential resistance area. | Above it, targets to the upside are $2.20, $2.30, $2.40 and then the pre-market high at $2.60. Beyond that, $3 and $3.30 come into play. | Below $2.03, targets to the downside are $1.80, $1.60, $1.48, $1.35 and then a gap fill at $1.20. | | | | ZAPP - 2nd day play: Up over 50% on technical breakout and short squeeze | Zapp Electric Vehicles Group Limited (ZAPP) designs, manufactures, and sells electric vehicles. It offers i300 electric urban motorcycles. The company was founded in 2017 and is based in Bangkok, Thailand. | ZAPP closed yesterday up over 127% on a technical breakout and no news, with the last press release 19 days ago when the company reported earnings. | According to Finviz, ZAPP has a short interest of over 59%. | ZAPP closed yesterday near the highs of the day, and given this move has been made on no news, perhaps old and new shorts drawn in yesterday are fueling this move high with ZAPP gapping up over 50% in the pre-market this morning. | This is one to have on your radar this morning with plenty of volatility expected. | | The first target for bulls is the pre-market high of $15.65. Beyond that, $16, $18 and $20 come into play. | Below $15.65, targets to the downside are $15, $14, $13, $12, $11.50, $11, $10, $9 and $8.32. Below that, $8, $7 and $6 come into play. | | MARKET NEWS 📰 | | | 👊 Make sure you are getting my mobile text alerts – text "RAGE" to 1-(888) 404-5747 to get all of my latest HOT STOCK ideas delivered right to your phone (make sure you put the "1" at the front!). Don't miss out! | | Questions or concerns about our products? Email Support@360wallstreet.io © Copyright 2022, RagingBull | | *Just so you know, what you're reading is curated content for which we have received a monetary fee (detailed below) to create and distribute. Let's be clear that investing can be quite the roller coaster as stock prices can have wild swings up and down, so consider those crucial risks before you ever consider trading anything we discuss. Make sure you check out our full disclosure down below for the details on how we were paid, the risks, and why these results aren't what you'd call "typical." | Just a quick heads up about this ad you're reading—as we've said, even though we like the company referenced above, and all the facts we discussed above are true to the best of our knowledge, we are running a business here. To distribute this information and help offset the costs of maintaining our large digital audience, in advance of writing the content above, we currently have received twenty-five thousand dollars (cash) from Sica Media for advertising MAIA Biotechnology, Inc for a one day marketing program on July 9, 2024. Previously, we received fifteen thousand dollars (cash) from Sica Media for advertising MAIA Biotechnology, Inc for a one day marketing program on June 13, 2024. Previously, we received twelve thousand five hundred dollars (cash) from Sica Media for advertising MAIA Biotechnology, Inc for a one day marketing program on June 7, 2024. Also, we were paid fifteen thousand dollars from Sica Media who was compensated by a third party not affiliated with the Company for advertising MAIA Biotechnology, Inc for a one day marketing program on March 6, 2024. We were also previously paid fourteen thousand dollars from Sica Media who was compensated by a third party not affiliated with the Company for advertising MAIA Biotechnology, Inc from a period beginning on November 15 through November 18, 2023, and also fifteen thousand dollars from Sica Media who was compensated by a third party not affiliated with the Company for advertising MAIA Biotechnology, Inc from a period beginning on October 12 through October 13, 2023. These amounts were paid by someone else not connected to MAIA Biotechnology, Inc. It might be obvious, but whoever paid for this might own shares and is likely looking to sell some or all of them at any time after we send out this information, which might affect the stock price. We may also buy or sell shares in the company at some point in the future, although neither RagingBull nor its owners own any shares of the company at this time. Also, keep in mind that due to the sheer size of our audience, if even a small percentage of people decide they want to buy this stock, it could potentially boost interest enough to hike up those share prices and cause a temporary spike, and the opposite is possible as our program ends, though that is not always the case. | Now, diving right into MAIA Biotechnology, Inc might sound exciting. But remember, it's like venturing into the wilderness—be aware that there's exceptional risk involved in trading. This isn't small potatoes we're talking about; you could lose every dime you put in, so always carefully think about what you're doing. That's why they call this trading, after all. We're shining a light on the good stuff about the company here, but it's on you to do your homework, make your own calls, and determine a plan for your own trading, hopefully with the help of your professional 1nvestment advis0r. | Oh, that brings us to another crucial point—we're not here to tell you (or even recommend) what you should do with your hard-earned money. We're simply sharing our non-expert thoughts by highlighting some companies we like that could use some help telling their story to more people. We're obviously biased in our writing. We're not here to dig into anything that may be negative about the company; this is advertising, after all! Also, keep in mind that if we make some predictions about the future, these are technically known as "forward-L00king statements" under the securities acts, so take those with a grain of salt. As with all forecasts, they're not set in stone, often wrong, and we certainly can't know where the Company's earnings, business, or share price will be tomorrow or a year from now. | Everything you read from us is all for your education, information, and possible entertainment. While we believe the info is reliable and accurate, we can't wear a cape and guarantee it. Before you jump into anything, make sure to talk it over with a pro—someone you trust who's licensed to give you real advice. To be clear, | Neither Raging Bull nor its owners, employees, or independent contractors are registered as a secur1ties br0ker-dealer, br0ker, 1nvestment advis0r (IA), or IA rep's with the SEC, any state securities regulat0ry authority, or any self-regulat0ry organization. | So, that's the scoop! If you're intrigued and want to learn more about the companies we talk about, hit up the SEC's website to dig into their filings and see the full picture. |
|
Post a Comment
Post a Comment